News & Updates

In patients with recurrent or metastatic inoperable head and neck squamous cell carcinoma (HNSCC), treatment with the novel antiangiogenic agent apatinib appears to be effective, leading to high rates of disease control, a recent study has found.

The combination of atezolizumab plus bevacizumab demonstrates promising antitumour activity in patients with advanced mucosal melanoma while having a manageable safety profile, according to the results of a phase II study.

Residential exposure to fine particulate matter with an aerodynamic diameter of ≤2.5 μm (PM2.5) appear to elevate the risk of lung adenocarcinoma in women, suggests a Taiwan study.

New drug applications approved by US FDA as of 16 - 31 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A plant-forward diet called EAT-Lancet appears to confer protective benefits against cancer only among females and shows no association with cardiovascular disease (CVD), a recent study has shown.

Combining pembrolizumab with chemoradiation therapy (CRT) showed a trend toward improved event-free survival (EFS) compared with CRT alone in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), primary results of the phase III KEYNOTE-412 trial showed.